NovaBridge Biosciences NBP
NASDAQ NBP
$1.80 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

NovaBridge Biosciences (NBP) Net Cash Flow (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Net Cash Flow of -$17.6 million for Q4 2025, down 69.61% year-over-year from -$58.0 million in Q4 2024, and down 128.15% quarter-over-quarter from $62.6 million in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

NovaBridge Biosciences (NBP) Net Cash Flow (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Net Cash Flow for 4 consecutive years, with -$17.6 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Net Cash Flow fell 69.61% year-over-year to -$17.6 million; the TTM figure through Dec 2025 stood at $45.0 million (up 153.78% YoY), while the FY2025 annual figure was $142.1 million, up 175.44% from the prior year.
  • Net Cash Flow fell to -$17.6 million in Q4 2025 per NBP's latest filing, from $62.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $62.6 million in Q3 2025 and bottomed at -$73.2 million in Q3 2024.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 652.90 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -504.30 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -183.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 374.50 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 407.41 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -496,000.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - 225.59 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -37.14 Mn
10 NovaBridge Biosciences 197.68 Mn 197.68 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -17.62 Mn
Sep 30, 2025 62.59 Mn
Dec 31, 2024 -11.06 Mn
Sep 30, 2024 -73.23 Mn
Dec 31, 2020 289.03 Mn
Sep 30, 2020 239.14 Mn
Dec 31, 2019 -3.60 Mn